Rucaparib Maintenance Therapy for Platinum-Sensitive Ovarian Cancer
Posted: Thursday, March 22, 2018
Results from ARIEL3, a randomized, phase III trial published in The Lancet, provide mounting evidence for the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients with recurrent ovarian cancer. Rucaparib maintenance therapy significantly improved progression-free survival compared with placebo among BRCA-mutated and homologous recombination–deficient populations with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
“These results reinforce rucaparib’s potential to provide an enduring and significant clinical benefit in women with advanced ovarian cancer, regardless of their tumor genetics,” concluded lead author Jonathan Ledermann, MD, of the University College London Hospital, in an interview with The ASCO Post. The authors added that maintenance therapy with this PARP inhibitor may represent a new standard of care in this patient population after response to second-line or later platinum-based chemotherapy.
The investigators evaluated 564 patients from 87 hospitals across 11 nations. Eligible patients achieved a partial or complete response after two or more platinum-based chemotherapy regimens.
In patients with a BRCA-mutant carcinoma (n = 196), median progression-free survival was 16.6 months in the rucaparib arm versus 5.4 months in the placebo group. Patients with homologous recombination–deficient carcinoma (n = 354) had a median progression-free survival of 13.6 months in the treatment group versus 5.4 months in the placebo group. Similarly, among the entire intent-to-treat population, rucaparib reduced the risk of disease progression by 64%, with a median progression-free survival of 10.8 months versus 5.4 months with placebo.